Arch Biopartners Inc V.ARCH

MetaBlok - A Pathway to an unmet 20 billion market

[Riverfolk]

This past week Arch Biopartners released a glimpse of the human data waiting on publication from a third party, that should be expected shortly. This data was further validated by CATCO when they sponored a new Covid19 trial which is fully funded by the Canadian Institutes of Health Research. The comparable Phase III study is exciting because the data which highlights the difference (6.7 days) in ventilation-free days was favouring the LSALT group vs Placebo. An open label study in conjunction with the World Health Organization's (WHO) Solidarity trial allows a pathway to a new standard of care providing additional positive signals above that of what is currently given to patients. 

Taking us back to the original thrid party publication  in The Cell when Metablok was proven in animal studies to have potential in treating organ inflammation. Meaning that the same mechanism of action that works in lung also works in the liver and KIDNEY

The Lung


The Liver


The Kidney



The reason that I have become even more bullish on the potential with Arch Biopartners, is that the original intent was to pursue a Kidney trial as it had the strongest animal data. The company stepped up to the global stage to help in the fight against Covid19 and ran a Lung trial because the animal data provided the opportunity. Given now that we know the technology is real with the release of the Phase II data, this novel therapeutic for organ inflammation can impact the market at a much larger scale. If the lung was validated, then in theory it drammatically derisks the Liver and Kidney.

• Currently, no specific therapies exist to prevent AKI in the world today. Management of AKI is supportive and includes life-sustaining therapy with dialysis. Patients that experience AKI are at high risk of developing chronic kidney disease, adverse cardiovascular outcomes and death.The worldwide market for AKI is estimated to be over $20 billion USD per year. ($325.4 dollars a share)
• CEO of Arch Biopartners, Richard Muruve, commented, “With the license of Telara’s cilastatin patent rights combined with our own, we look forward to doing a significant Phase II trial targeting ischemia reperfusion related AKI. Currently, there are no effective treatments to prevent AKI and Arch now has both Metablok and cilastatin that can be used in separate patient arms of a new Phase II trial. The collaboration with Telara will also facilitate a future drug application in Europe and potential patient recruitment in Spain.”

 The potential this novel therapeutic has as a one stop shop in organ inflammation is incredible and I look forward to the upcoming trial to continue to build shareholder wealth.

I am a shareholder, this is not investing advice and contains opinions, Do your own Due Diligence, I have provided mine in a previous post.